412
Participants
Start Date
August 21, 2019
Primary Completion Date
December 2, 2022
Study Completion Date
December 2, 2022
Certolizumab pegol
Active Substance: Certolizumab Pegol Pharmaceutical Form: Prefilled syringe Concentration: 200 mg/ml Route of Administration: Subcutaneous injection
Ps0026 101, Brussels
Ps0026 103, Brussels
Ps0026 107, Brussels
Ps0026 102, Leuven
Ps0026 110, Maldegem
Ps0026 109, Mons
Ps0026 104, Namur
Ps0026 208, London
Ps0026 209, London
Ps0026 201, Markham
Ps0026 210, Newmarket
Ps0026 203, St. John's
Ps0026 212, Toronto
Ps0026 205, Waterloo
Ps0026 204, Winnipeg
Ps0026 301, Prague
Ps0026 303, Prague
Ps0026 302, Uherské Hradiště
Ps0026 408, Amiens
Ps0026 404, Lorient
Ps0026 409, Poitiers
Ps0026 403, Rennes
Ps0026 407, Toulon
Ps0026 512, Bielefeld
Ps0026 532, Bogen
Ps0026 525, Dresden
Ps0026 506, Düren
Ps0026 521, Freiburg im Breisgau
Ps0026 529, Gladbeck
Ps0026 523, Hamburg
Ps0026 518, Karlsruhe
Ps0026 519, Leipzig
Ps0026 537, Magdeburg
Ps0026 530, Memmingen
Ps0026 516, Merzig
Ps0026 517, München
Ps0026 527, München
Ps0026 515, Nuremberg
Ps0026 501, Potsdam
Ps0026 511, Quedlinburg
Ps0026 505, Remscheid
Ps0026 603, Athens
Ps0026 609, Athens
Ps0026 610, Athens
Ps0026 601, Chaïdári
Ps0026 606, Larissa
Ps0026 608, Pátrai
Ps0026 607, Piraeus
Ps0026 604, Thessaloniki
Ps0026 605, Thessaloniki
Ps0026 707, Bari
Ps0026 714, Bologna
Ps0026 711, Brescia
Ps0026 712, Catania
Ps0026 710, Florence
Ps0026 702, Genova
Ps0026 706, L’Aquila
Ps0026 701, Napoli
Ps0026 709, Roma
Ps0026 713, Roma
Ps0026 704, San Donato Milanese
Ps0026 715, Torino
Ps0026 708, Torrette DI Ancona
Ps0026 807, Badalona
Ps0026 809, Barcelona
Ps0026 812, Barcelona
Ps0026 804, Pontevedra
Ps0026 806, Sant Joan Despí
Ps0026 818, Vigo
Ps0026 902, Bradford
Ps0026 909, Dunfermline
Ps0026 914, Glasgow
Ps0026 916, Hertfordshire
Ps0026 911, Kingston upon Thames
Ps0026 905, Leeds
Ps0026 904, Newcastle upon Tyne
Ps0026 901, Salford
Ps0026 915, Wakefield
Ps0026 908, York
UCB Biopharma SRL
INDUSTRY